Experience with denosumab (XGEVA®) for prevention of skeletal-related events in the 10 years after approval.
- DOI
- 10.1016/j.jbo.2022.100416
- Published
- 2022 Apr
- Container
- Journal of bone oncology
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.jbo.2022.100416,
title = {Experience with denosumab (XGEVA®) for prevention of skeletal-related events in the 10 years after approval.},
author = {Cadieux B and Coleman R and Jafarinasabian P and Lipton A and Orlowski RZ and Saad F and Scagliotti GV and Shimizu K and Stopeck A},
year = {2022},
journal = {Journal of bone oncology},
doi = {10.1016/j.jbo.2022.100416},
url = {https://doi.org/10.1016/j.jbo.2022.100416}
}RIS
TY - JOUR TI - Experience with denosumab (XGEVA®) for prevention of skeletal-related events in the 10 years after approval. AU - Cadieux B AU - Coleman R AU - Jafarinasabian P AU - Lipton A AU - Orlowski RZ AU - Saad F AU - Scagliotti GV AU - Shimizu K AU - Stopeck A PY - 2022 JO - Journal of bone oncology DO - 10.1016/j.jbo.2022.100416 UR - https://doi.org/10.1016/j.jbo.2022.100416 ER -
APA
B, C., R, C., P, J., A, L., RZ, O., F, S., GV, S., K, S., & A, S. (2022). Experience with denosumab (XGEVA®) for prevention of skeletal-related events in the 10 years after approval.. Journal of bone oncology. https://doi.org/10.1016/j.jbo.2022.100416
Source records
- pubmed · retrieved 2026-09-26T12:53:32.512Z